Literature DB >> 26348558

Effects of ketamine on cognition-emotion interaction in the brain.

Milan Scheidegger1, Anke Henning2, Martin Walter3, Heinz Boeker4, Anne Weigand5, Erich Seifritz6, Simone Grimm7.   

Abstract

Cognition-emotion interaction in the brain can be investigated by incorporating stimuli with emotional content into cognitive tasks. Emotional stimuli in the context of a working memory (WM) task yield increased activation in WM-related lateral prefrontal regions, whereas cognitive effort enhances deactivation in emotion-related cortical midline regions. N-methyl-d-aspartate glutamate receptors (NMDA-Rs) are critically involved in WM, and NMDA-R antagonists, such as ketamine, accordingly affect WM but also have a profound impact on emotional processing, as underscored by the rapid reduction of depressive symptoms after administration of a single dose of ketamine. The effect of ketamine on both cognitive and emotional processing therefore makes it a useful tool to further explore cognition-emotion interaction in the brain. Twenty-three healthy subjects were administered ketamine to investigate whether its effects on WM performance and brain reactivity depend on emotional content or emotional valence of stimuli. Furthermore, we aimed at investigating how ketamine affects the integration of emotion and WM processes in emotion-related cortical midline regions and WM-related lateral prefrontal regions. Results show that ketamine modulates cognition-emotion interaction in the brain by inducing lateralized and valence-specific effects in emotion-related cortical midline regions, WM-related lateral prefrontal regions and insula. In emotion-related cortical midline regions ketamine abolishes enhancement of deactivation normally observed during cognitive effort, while in the right DLPFC and the left insula the previously described pattern of increased activation due to emotional content is abrogated exclusively for negative stimuli. Our data therefore shows a specific effect of ketamine on cognition-emotion interaction in the brain and indicates that its effect on amelioration of negative biases in MDD patients might be related to less interference of cognitive processing by negative emotional content.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition–emotion interaction; Ketamine; Working memory

Mesh:

Substances:

Year:  2015        PMID: 26348558     DOI: 10.1016/j.neuroimage.2015.08.070

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  16 in total

Review 1.  How do antidepressants work? New perspectives for refining future treatment approaches.

Authors:  Catherine J Harmer; Ronald S Duman; Philip J Cowen
Journal:  Lancet Psychiatry       Date:  2017-01-31       Impact factor: 27.083

2.  Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.

Authors:  Meng Li; Liliana Ramona Demenescu; Lejla Colic; Coraline Danielle Metzger; Hans-Jochen Heinze; Johann Steiner; Oliver Speck; Anna Fejtova; Giacomo Salvadore; Martin Walter
Journal:  Neuropsychopharmacology       Date:  2016-09-08       Impact factor: 7.853

Review 3.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

4.  Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.

Authors:  Jessica L Reed; Allison C Nugent; Maura L Furey; Joanna E Szczepanik; Jennifer W Evans; Carlos A Zarate
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-01-25

5.  Effects of Acute Drug Administration on Emotion: A Review of Pharmacological MRI Studies.

Authors:  Kathryne Van Hedger; Leah M Mayo; Anya K Bershad; Racheal Madray; Harriet de Wit
Journal:  Curr Addict Rep       Date:  2021-03-14

6.  PsychotherapyPlus: augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial.

Authors:  Malek Bajbouj; Sabine Aust; Jan Spies; Ana-Lucia Herrera-Melendez; Sarah V Mayer; Maike Peters; Christian Plewnia; Andreas J Fallgatter; Lukas Frase; Claus Normann; Nora Behler; Linda Wulf; Eva-Lotta Brakemeier; Frank Padberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-12-06       Impact factor: 5.270

7.  Aberrant working memory processing in major depression: evidence from multivoxel pattern classification.

Authors:  Matti Gärtner; M Elisabetta Ghisu; Milan Scheidegger; Luisa Bönke; Yan Fan; Anna Stippl; Ana-Lucia Herrera-Melendez; Sophie Metz; Emilia Winnebeck; Maria Fissler; Anke Henning; Malek Bajbouj; Karsten Borgwardt; Thorsten Barnhofer; Simone Grimm
Journal:  Neuropsychopharmacology       Date:  2018-05-02       Impact factor: 7.853

8.  Effects of subthalamic nucleus deep brain stimulation on emotional working memory capacity and mood in patients with Parkinson's disease.

Authors:  Angela Merkl; Eva Röck; Tanja Schmitz-Hübsch; Gerd-Helge Schneider; Andrea A Kühn
Journal:  Neuropsychiatr Dis Treat       Date:  2017-06-19       Impact factor: 2.570

9.  Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.

Authors:  Jessica L Reed; Allison C Nugent; Maura L Furey; Joanna E Szczepanik; Jennifer W Evans; Carlos A Zarate
Journal:  Neuroimage Clin       Date:  2018-07-05       Impact factor: 4.881

10.  Species-conserved reconfigurations of brain network topology induced by ketamine.

Authors:  R Becker; U Braun; A J Schwarz; N Gass; J I Schweiger; W Weber-Fahr; E Schenker; M Spedding; C Clemm von Hohenberg; C Risterucci; Z Zang; O Grimm; H Tost; A Sartorius; A Meyer-Lindenberg
Journal:  Transl Psychiatry       Date:  2016-04-19       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.